News from Thursday, February 9, 2023
Articles
Health Affairs Spending Council Releases Its Road Map For Action
(2/8, Health Affairs Forefront) comments “...Recently, the nonpartisan twenty-one member council, chaired by former Senate Majority Leader William Frist (R-TN) and former Food and Drug Administration Administrator Margaret Hamburg, released those final recommendations in a report titled ‘A Road Map For Action.’...Several of the specific recommendations overlap with policy approaches identified by the Congressional Budget Office that federal lawmakers could adopt to reduce health care prices...The work of the Health Affairs Council On Health Care Spending and Value, including the briefing, was supported by the National Pharmaceutical Council and Elevance Health.” Full
UK: NICE Blocks Wider Use of Jardiance, Forxiga in Heart Failure
(2/9, Phil Taylor, PharmaPhorum) reports “Eli Lilly and Boehringer Ingelheim's Jardiance and AstraZeneca's Forxiga have not been recommended for NHS use as a treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in new draft guidance...Boehringer and Lilly said they were disappointed by the decision, particularly as there are currently no clinically proven medications recommended by NICE for people with preserved or mildly reduced ejection fraction CHF.” Full
EU HTA: Business as Usual for Market Access Strategy or Time for Change?
(2/9, Rebecca Coady, IQVIA Blog) comments “...To answer this question, we need to examine the potential interplay and impact of [Joint Clinical Assessment] on [EU Member States] evidence requirements and pricing and reimbursement processes and decision making. Currently we know that each MS will retain sole responsibility for conclusions on overall clinical added value and P&R. However, to date, few MS and HTA bodies have communicated plans around implementation of the JCA process in their national procedures. Therefore, at this early stage, the interplay is difficult to predict as such this blog investigates three key areas of uncertainty that could impact market access strategies.” Full
Press Releases
EveryLife Foundation and IVI Announce Rare Disease Initiative
(2/8, EveryLife Foundation Press Release) “The Innovation and Value Initiative, a non-profit research organization committed to advancing research that focuses on the patient experience, is announcing their Engaging Patients with Rare Disease in Identifying Meaningful Approaches to CER and Value Assessment launch as part of their Rare Disease Initiative, made possible through funding support from the Eugene Washington PCORI Engagement Awards program...IVI and EveryLife will serve as co-chairs of the steering committee and work together with patients and other stakeholders in a series of roundtable dialogues to inform project outcomes.” Full
Journals
Long-Term Comparison of Cilostazol versus Clopidogrel in Secondary Prevention of Noncardioembolic Ischemic Stroke
Yu Jeong Lee, Nam Kyung Je
February 8, 2023, medRxiv
Comments on A Conceptual Framework for Life-Cycle Health Technology Assessment
Thi Hao Pham, MSc, Jurjen van der Schans, PhD
February 9, 2023, Value in Health
Events
Webinar: How to Supercharge Real World Evidence Generation in Phase IV Trials
March 16, 2023
11:00AM EDT